Direct-to-Employer Drug Programs (DTE)
The pharmaceutical supply chain is changing. Manufacturers are building direct channels to reach patients - and increasingly, to reach the employers who fund their benefits. But most of what the market calls "Direct-to-Employer" today is clinical program management layered on top of manufacturer pricing - not true benefit integration. For employers managing pharmacy spend, understanding this distinction is critical.
Three Direct Channels: DTC, DTP, and DTE
The industry uses three related but distinct terms for manufacturer-direct programs. Understanding the differences matters because each has different implications for employer plans, member experience, and benefit integration.
Direct-to-Consumer (DTC)
DTC programs make medications available to individual consumers at manufacturer-set prices, typically through a dedicated website or coupon program. Examples include TrumpRx, GoodRx manufacturer pricing, and manufacturer copay cards. The consumer pays cash or uses a coupon. The transaction sits entirely outside the employer-sponsored benefit - it does not apply to deductibles or out-of-pocket maximums, and it is invisible to the plan.
Direct-to-Patient (DTP)
DTP programs add clinical services to the DTC model. The manufacturer or a partner provides telehealth for diagnosis and prescribing, then manages the prescription, shipping, patient support, and ongoing monitoring. LillyDirect and NovoCare are prominent DTP examples. Eli Lilly reports that a significant and growing share of Zepbound prescriptions now come through its direct platform. Like DTC, most DTP programs currently sit outside the employer benefit.
Direct-to-Employer (DTE)
DTE programs bring manufacturer pricing inside employer-sponsored health plans, bypassing traditional PBM adjudication for targeted drug categories. Unlike DTC and DTP, the transaction is integrated into the benefit - member cost-share applies to deductibles and accumulators, and the plan sponsor has visibility into the actual cost.
In practice, most manufacturers will not contract directly with individual employers. Doing so risks creating channel conflict with their existing PBM relationships - the same PBMs that control formulary access for the manufacturer's broader portfolio. Instead, manufacturers typically work through benefit administrators that can facilitate a compliant DTE model - handling eRx intake, eligibility, cost-share, accumulator reporting, and claims settlement on behalf of the employer plan while maintaining the manufacturer's pricing structure.
This is an important distinction: DTE does not necessarily mean the manufacturer and the employer sign a direct contract. It means the manufacturer's pricing reaches the employer's benefit through infrastructure that sits outside traditional PBM adjudication.
Why Manufacturers Are Going Direct
Three forces are driving the shift toward direct channels:
PBM economics no longer serve manufacturer interests in every category. For high-cost specialty and GLP-1 medications, manufacturers have found that PBM formulary placement - which traditionally required large rebates - is not the only path to market access. Direct channels offer an alternative that can be more cost-effective for the manufacturer while delivering a lower net price to the employer and patient.
Regulatory tailwinds are accelerating direct models. In January 2026, HHS issued guidance clarifying that manufacturers can offer lower-cost drugs directly to patients - including Medicare and Medicaid enrollees - in a manner that is low risk under the federal anti-kickback statute. The Consolidated Appropriations Act of 2026 requires 100% rebate pass-through, which reduces the financial advantage of rebate-heavy PBM arrangements. TrumpRx launched in February 2026 with most-favored-nation pricing from major manufacturers.
The economics are compelling. When a manufacturer sells a GLP-1 medication through the traditional PBM channel, the employer's net cost after rebate may still be $750+ per month - and that number is difficult to verify in real time. Through a DTE program, the manufacturer might offer the same medication at ~$550 with no rebate - a lower net cost with complete price transparency and no reconciliation required.
The Problem With Current DTE Models
Most current DTE models have a critical gap: they exist outside the employer's benefit infrastructure. This creates several problems:
Clinical management is not benefit integration. Many vendors marketed as "DTE" provide clinical program management - prior authorization, adherence monitoring, patient onboarding - but do not integrate the transaction into the employer's benefit. Clinical wrapping does not make a program part of the benefit. Without eRx intake, cost-share collection, accumulator reporting, and claims settlement, the program is still outside the plan.
Accumulator disconnection. If a member's cost-share for a DTE prescription does not apply to their deductible or out-of-pocket maximum, the member is effectively paying twice - once for the DTE medication and again toward a deductible that does not reflect their actual spending.
No integration with plan administration. DTE transactions that sit outside the TPA's claims system create data gaps. The employer cannot see the full picture of its pharmacy spend. The TPA cannot coordinate benefits. Stop-loss carriers cannot assess exposure.
No independent verification. When a DTE program claims to offer the "lowest price," there is no independent mechanism to verify that claim against all other available channels in real time. The employer is trusting the manufacturer's assertion rather than seeing a comparative evaluation.
Pharmacy exclusion. Most manufacturer-direct models use one or two nationally contracted mail-order pharmacies. Independent community pharmacies are cut out of the supply chain entirely, even though they are often the patient's preferred and most accessible dispensing point.
What Infrastructure Is Required to Bring DTE Inside the Benefit
For DTE to work as a true benefit integration - not just a cash-pay workaround - several operational components must be in place:
eRx intake. The system must receive prescriptions through the standard e-prescribing workflow (NCPDP SCRIPT), just like any other pharmacy channel. Prescribers should not need to use a separate process.
Eligibility verification. The member's benefit eligibility must be verified in real time against the employer's plan enrollment data.
Cost-share calculation and collection. The member's cost-share (copay, coinsurance, deductible application) must be calculated according to the plan's benefit design and collected at the point of service.
Accumulator reporting. The member's cost-share must be reported to the plan's accumulators - deductible, out-of-pocket maximum - so it is reflected in their benefit status across all providers.
Claims settlement. The plan's portion must be settled through either the TPA's medical claims system or the PBM's pharmacy claims system - depending on the employer's plan administration model. Both paths require data continuity, stop-loss reporting, and financial reconciliation.
Supplier settlement. Payment to the manufacturer or its logistics partner must be processed with transparent, pass-through economics - no spread, no retained margin.
Decision-level documentation. For each prescription routed through a DTE channel, the system must document why that channel was selected, what other channels were evaluated, and what the net cost comparison showed.
Without this infrastructure, DTE is just a manufacturer coupon dressed up as a benefit. With it, DTE becomes a genuine channel option that can be evaluated alongside PBM specialty, PBM mail, retail, and independent pharmacy.
The Role of Independent Pharmacy in DTE
One of the most overlooked aspects of DTE is what happens at the pharmacy level. In most manufacturer-direct models, the medication ships from the manufacturer's logistics partner directly to the patient. The local pharmacy is bypassed entirely.
This creates a structural problem: the patient loses their relationship with their community pharmacist, and the independent pharmacy loses revenue from prescriptions it would otherwise dispense.
An alternative model preserves independent pharmacy involvement through a Pharmacy of Record (POR) structure. In this model, the independent pharmacy performs the clinical functions - drug utilization review, patient counseling, medication therapy management - while the physical product ships from the manufacturer's logistics network. The pharmacy earns a POR fee for clinical services rather than a dispensing margin.
This structure keeps independent pharmacies inside the DTE supply chain, maintains the patient-pharmacist relationship, and ensures clinical oversight at the local level - while still delivering the cost advantages of manufacturer-direct pricing.
How DTE Relates to Drug Benefit Integrity
The Drug Benefit Integrity (DBI) standard requires that manufacturer-direct programs be evaluated alongside all other channels at the point of decision - not treated as a separate, out-of-benefit program. This is DBI's third requirement.
When DTE programs are integrated into the routing evaluation, the plan sponsor can see the actual net cost comparison: DTE price vs. PBM specialty price vs. PBM mail price vs. retail price. The routing decision is documented, and the plan sponsor has proof that the selected channel - whether DTE or not - was the lowest net cost option.
Without this integration, DTE programs exist in a parallel universe where the employer trusts the manufacturer's pricing claim without independent verification. With DBI-compliant infrastructure, DTE becomes one evaluated channel among many - and the plan sponsor has the decision-level documentation to prove it.
Frequently Asked Questions
DTE is a model where manufacturer pricing reaches employer-sponsored health plans through infrastructure that bypasses traditional PBM adjudication. In practice, most manufacturers do not contract directly with individual employers - they work through benefit administrators that facilitate a compliant DTE model. The employer gets a negotiated price, and the transaction is integrated into the benefit so member cost-share applies to deductibles and accumulators.
Usually not. Most manufacturers avoid direct contracts with individual employers because doing so risks creating channel conflict with their existing PBM relationships - the same PBMs that control formulary access for the manufacturer's broader portfolio. Instead, manufacturers typically work through benefit administrators that can facilitate DTE pricing while handling eRx intake, eligibility, cost-share, accumulator reporting, and claims settlement on behalf of the employer plan.
A DTE clinical vendor provides clinical program management - prior authorization, adherence monitoring, patient onboarding, outcomes tracking - but does not integrate the transaction into the employer's benefit. DTE benefit infrastructure handles the operational requirements to make the transaction part of the covered benefit: eRx intake, eligibility verification, cost-share collection, accumulator reporting, claims settlement, and supplier payment. Clinical management and benefit infrastructure are complementary but distinct - and without the infrastructure, the program is still outside the plan.
DTC (Direct-to-Consumer) sells to individual consumers outside the benefit. DTP (Direct-to-Patient) adds telehealth and clinical services but typically still sits outside the benefit. DTE integrates directly with the employer's plan, making manufacturer pricing part of the covered benefit.
Currently, DTE programs are most common for high-cost specialty medications and GLP-1 drugs for obesity and diabetes. Manufacturers including Eli Lilly, Novo Nordisk, AstraZeneca, and Pfizer have announced or launched direct pricing programs. The category is expanding rapidly.
No. DTE is an additional channel that can be evaluated alongside PBM specialty, PBM mail, retail, and independent pharmacy. The PBM continues to manage the broader formulary. DTE is most relevant for the high-cost drugs where the manufacturer's direct price may be lower than the PBM net cost.
ApalyRx provides the turn-key infrastructure to bring DTE programs inside the benefit - eRx intake, eligibility verification, cost-share collection, accumulator reporting, claims settlement through either the TPA or PBM, and supplier settlement. It evaluates DTE alongside all other channels in real time and documents every routing decision.
In a Pharmacy of Record (POR) structure, an independent community pharmacy performs clinical functions - drug utilization review, patient counseling, medication therapy management - while the physical medication ships from the manufacturer's logistics network. The pharmacy earns a POR fee for clinical services.
When properly integrated into the benefit with accumulator reporting, claims data continuity, and decision-level documentation, DTE programs can support ERISA fiduciary compliance. The key is infrastructure that treats DTE as a verified channel option, not an unaudited side arrangement.
Bring Manufacturer-Direct Programs Inside Your Benefit
See how ApalyRx provides turn-key DTE infrastructure with real-time routing across all channels.
Request a Conversation